Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis

Li,Xiaoming; Liu,Yaoming; Wu,Bin; Dong,Zhilong; Wang,Yichen; Lu,Jianzhong; Shi,Ping; Bai,Wenlong; Wang,Zhiping

doi:10.3892/or.2014.3511

December-2014 Volume 32 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December-2014 Volume 32 Issue 6

Full Size Image

Article

Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis

Authors:
- Xiaoming Li
- Yaoming Liu
- Bin Wu
- Zhilong Dong
- Yichen Wang
- Jianzhong Lu
- Ping Shi
- Wenlong Bai
- Zhiping Wang
View Affiliations / Copyright

Affiliations: Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, Lanzhou, Gansu 730000, P.R. China, Department of Orthopedics, Anning Hospital, General Hospital of Lanzhou Military Command, Lanzhou, Gansu 730070, P.R. China, Department of Orthopedics, Shanghai Jiangong Hospital, Shanghai 200083, P.R. China, Department of Pathology and Cell Biology, University of South Florida, Tampa, FL 33612, USA
Pages: 2605-2611
|
Published online on: September 23, 2014

https://doi.org/10.3892/or.2014.3511
Expand metrics +

Abstract

Receptor activator of NF-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) are key regulators of bone metabolism under both normal and pathological conditions, including prostate cancer (PCa) bone metastases. However, little is known concerning the expression and function of these regulators in prostate tumor samples and PCa cells and their correlation with invasion and bone metastasis. In the present study, we determined the expression of RANK, RANKL and OPG in 3 human PCa cell lines and 40 PCa patient samples by immunohistochemistry and enzyme-linked immunosorbent assay (ELISA). As controls, samples from 20 patients with benign prostate hyperplasia (BPH) and normal prostate epithelial RWPE2 cells were also included in the analyses. The effects of soluble RANKL (sRANKL) and OPG as well as RANK knockdown on PCa invasion were examined in Transwell assays. Immunohistochemical staining detected little RANK, OPG and RANKL expression in hyperplasia prostate while the percentages of positivity were increased to 50, 45 and 52.5%, respectively, in prostate tumor tissues. OPG and sRANKL levels in the prostate tumor samples as measured by ELISA were ~10-fold that in the BPHs (P<0.01) and the levels were higher in aggressive tumors than non-aggressive ones (P<0.05). The sRANKL level in the serum of PCa patients was the same as that in the patients with BPH, yet the serum OPG levels correlated with the tissue levels (R2=0.620, P<0.01, which both showed a 10-fold increase in PCa over BPH (P<0.01) with higher levels in aggressive PCa than non-aggressive ones (P<0.05). Consistent with the tissue analyses, expression levels of RANK mRNA and protein were detected in multiple human PCa cell lines by RT-PCR and western blotting, respectively. The treatment of PCa cells with RANKL significantly increased the number of invaded cells (P<0.01), which was suppressed by the decoy receptor OPG. RANK siRNA transfection dramatically dampened the stimulatory effect of RANKL on PCa cell invasion. Our findings indicate that the expression of RANK, RANKL and OPG may be used as diagnostic markers to identify patients at high risk for aggressive PCa and that the effective suppression of PCa cell migration by OPG via the blockage of RANKL activity represents a potential therapeutic strategy for interfering with prostate tumor metastasis and progression to bone.

View Figures

View References

1	Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1999. CA Cancer J Clin. 49:8–31. 1999. View Article : Google Scholar
2	Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2:584–593. 2002. View Article : Google Scholar : PubMed/NCBI
3	Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
4	Dougall WC and Chaisson M: The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev. 25:541–549. 2006. View Article : Google Scholar : PubMed/NCBI
5	Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T and Matsuoka M: Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor κB ligand on adult T-cell leukemia cells. Blood. 99:634–640. 2002.PubMed/NCBI
6	Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F and Heymann D: The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 15:457–475. 2004. View Article : Google Scholar : PubMed/NCBI
7	Morgan T, Atkins GJ, Trivett MK, et al: Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor κB. Am J Pathol. 167:117–128. 2005.PubMed/NCBI
8	Chen G, Sircar K, Aprikian A, Potti A, Goltzman D and Rabbani SA: Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 107:289–298. 2006. View Article : Google Scholar : PubMed/NCBI
9	Roux S and Mariette X: The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-κB) and RANK ligand expression. Leuk Lymphoma. 45:1111–1118. 2004.
10	Van Poznak C, Cross SS, Saggese M, et al: Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours. J Clin Pathol. 59:56–63. 2006.
11	Wittrant Y, Théoleyre S, Chipoy C, et al: RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta. 1704:49–57. 2004.PubMed/NCBI
12	Chen YC, Sosnoski DM and Mastro AM: Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 12:2152010. View Article : Google Scholar : PubMed/NCBI
13	Todenhofer T, Hennenlotter J, Schmiedel BJ, et al: Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases. Prostate. 73:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
14	Mountzios G, Dimopoulos MA, Bamias A, et al: Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 46:221–229. 2007.PubMed/NCBI
15	Jones DH, Nakashima T, Sanchez OH, et al: Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 440:692–696. 2006. View Article : Google Scholar : PubMed/NCBI
16	Santini D, Perrone G, Roato I, et al: Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol. 226:780–784. 2011.
17	Zhang J, Dai J, Qi Y, et al: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 107:1235–1244. 2001. View Article : Google Scholar : PubMed/NCBI
18	Fili S, Karalaki M and Schaller B: Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenviron-ment-related survival factors. Cancer Lett. 283:10–19. 2009. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles